Brandon Howard1, James Trussell2, ElizaBeth Grubb3, Maureen J Lage4. 1. Teva Global Medical Affairs, Frazer, PA 19355, USA. 2. Princeton University, Princeton, NJ 08544, USA; University of Hull, Hull HU6 7RX, England. Electronic address: trussell@princeton.edu. 3. Teva Global Health Economics and Outcomes Research, Kansas City, MO 64131, USA. 4. Health Metrics Outcomes Research, Bonita Springs, FL 34134, USA.
Abstract
OBJECTIVE: To evaluate pregnancy complication rates and related charges in users of 84/7, 21/7 and 24/4 combined oral contraceptives (COCs). STUDY DESIGN: Data were obtained from the i3 InVision Data Mart™ retrospective claims database. Subjects were aged 15-40 years, first prescribed a COC between 1/1/2006 and 4/1/2011 and continuously insured for ≥1 year. 84/7 users were matched 1:1 to 21/7 and 24/4 users. RESULTS: Pregnancy-related complication rates and associated charges were significantly lower with 84/7 vs. 21/7 and 24/4 regimens. CONCLUSION: Preliminary data suggest 84/7 regimens may be associated with fewer pregnancy complications and lower related charges.
OBJECTIVE: To evaluate pregnancy complication rates and related charges in users of 84/7, 21/7 and 24/4 combined oral contraceptives (COCs). STUDY DESIGN: Data were obtained from the i3 InVision Data Mart™ retrospective claims database. Subjects were aged 15-40 years, first prescribed a COC between 1/1/2006 and 4/1/2011 and continuously insured for ≥1 year. 84/7 users were matched 1:1 to 21/7 and 24/4 users. RESULTS: Pregnancy-related complication rates and associated charges were significantly lower with 84/7 vs. 21/7 and 24/4 regimens. CONCLUSION: Preliminary data suggest 84/7 regimens may be associated with fewer pregnancy complications and lower related charges.
Authors: Heather Fels; Rachel Steward; Alexander Melamed; Anna Granat; Frank Z Stanczyk; Daniel R Mishell Journal: Contraception Date: 2012-12-19 Impact factor: 3.375